The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy.

ABSTRACT:

Background

Concomitant high-dose cisplatin with radiotherapy is commonly used for treating head and neck squamous cell carcinoma (HNSCC). Cisplatin, often used with radiotherapy, is known for causing irreversible sensorineural hearing loss, with individual variability suggesting a genetic component. This study aims to enhance the predictive ability of the clinical prediction model for cisplatin-induced hearing loss (CIHL) in HNSCC patients, as outlined in Theunissen et al., by incorporating significant genetic variants.

Methods

Conducted at the Netherlands Cancer Institute, this retrospective study included 74 patients treated between 1997 and 2011. Thirty-one SNPs that were previously associated with CIHL or other cisplatin-induced toxicities were identified and incorporate

SUBMITTER: Duinkerken CW 

PROVIDER: S-EPMC11332395 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature